

Corporate and Shareholder Information



Stock Listing

The principal market for our Common Stock is the New York Stock Exchange (NYSE). Our stock is also traded on various United States regional stock exchanges.

Stock Transfer Agent and Registrar

Computershare
P.O. Box 30170
College Station, TX 77842-3170
Telephone: 1-800-733-9393
Outside the U.S., Canada and Puerto Rico: 1-781-575-4591
Internet: www.computershare.com/investor

Shareholder Services and Programs

Please contact our Stock Transfer Agent and Registrar, Computershare, with inquiries concerning shareholder accounts of record and stock transfer matters, and for information on the following services and programs:

- Computershare Investment Program
 - Direct purchase of Pfizer stock
 - Dividend reinvestment
 - Automatic monthly or bi-monthly investments
- Book-entry share ownership
- Direct deposit of dividends

Political Action Committee (PAC)

To review our most recent PAC and corporate political contributions report, go online at www.pfizer.com/pac.

Helplines

Patients, customers and health care professionals who have questions about any of our products should call 1-800-438-1985.

Patients in the U.S. who need help getting access to their Pfizer medicines should contact Pfizer RxPathways®. The program provides eligible patients with a range of support services including insurance counseling, co-pay help, providing Pfizer medicines for free or at a savings, and more. Pfizer RxPathways is a joint program of Pfizer Inc. and the Pfizer Patient Assistance Foundation™. Visit www.PfizerRxPathways.com or call 1-844-989-PATH (7284) to learn more.

Additional Information

You can find more information about Pfizer online:

- Website: www.pfizer.com
- Twitter: www.twitter.com/Pfizer
- Facebook: www.facebook.com/Pfizer
- LinkedIn: www.linkedin.com/company/pfizer

This Annual Review is produced by Pfizer's Corporate Affairs group.

Unless otherwise noted herein, the trademarks, logos and service marks appearing in the Annual Review, whether or not appearing with the trademark symbol, are owned or licensed by Pfizer Inc. or its affiliates.

KUBio® is a trademark of GE Healthcare Bioprocess R&D AB.

Remicade® is a trademark of Janssen Biotech, Inc.

Januvia® is a trademark of Merck Sharpe & Dohme Corp.

Forward-Looking Information

This Annual Review includes forward-looking statements about, among other things, our anticipated future operating and financial performance, business plans and prospects, and products and product candidates that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to Pfizer's Annual Report on Form 10-K for the year ended December 31, 2016, and Pfizer's subsequent reports on Form 10-Q, including the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results," as well as Pfizer's subsequent reports on Form 8-K for a description of the substantial risks and uncertainties related to the forward-looking statements included in this Annual Review. These reports are available on our website at www.pfizer.com and on the U.S. Securities and Exchange Commission's (SEC) website at www.sec.gov. The forward-looking statements in this Annual Review speak only as of the original date of this Annual Review and we undertake no obligation to update or revise any of these statements, except as required by law or the rules and regulations of the SEC.